Sign in
Taking people in United StatesPhase 2

Tests adding inotuzumab ozogamicin to treatment for new Ph+ acute lymphoblastic leukemia

Tests adding inotuzumab ozogamicin to standard treatment in adults newly diagnosed with Ph+ leukemia.

Key facts

Who runs it
University of Chicago
Where
Chicago, United StatesSee the site
Trial code
Registry title
Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
Status
Recruiting
Phase
Phase 2
People taking part
25 people, planned
Started
2 Mar 2021
Expected to end
1 Mar 2028
Type of study
Interventional, 5 groups
Treatments tested
  • Inotuzumab ozogamicin
  • Dasatinib
  • Dexamethasone
  • Methotrexate
  • Vincristine
  • Ponatinib
  • Purinethol (6-Mercaptopurine)
  • Prednisone
Record updated
5 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with newly diagnosed Ph+ B-cell acute lymphoblastic leukemia who have not been treated yet, to test adding inotuzumab ozogamicin (InO) to the first treatment.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Newly diagnosed, untreated Ph+ B-cell acute lymphoblastic leukemia with CD22 on ≥20% of blasts. Bone marrow with ≥20% lymphoblasts and BCR-ABL1 shown by FISH or PCR testing. ECOG performance status 0-2.
Earlier treatment
No earlier treatment for ALL, except up to 7 days of corticosteroids or hydroxyurea and one dose of intrathecal therapy. Must be at least 2 weeks from major surgery, radiation or other investigational trials.
Biomarker or test result
Ph+ (BCR-ABL1 positive) leukemia, shown by FISH or PCR-based testing, and CD22 on ≥20% of blasts.

Main reasons for not taking part

  • Leukemia only outside the bone marrow, Burkitt's or mixed-lineage leukemia
  • Active leukemia in the central nervous system
  • Active or chronic hepatitis B or C, or chronic liver disease, or past hepatic veno-occlusive disease
  • Uncontrolled heart disease or QTcF over 500 msec
  • Pregnant or breastfeeding women

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • Must be a newly diagnosed and untreated patient with Ph+ B-cell Acute Lymphoblastic Leukemia and CD22 expression on ≥20% of blasts
  • 18 years old or older
  • Bone marrow involvement with ≥20% lymphoblasts and demonstration of BCR-ABL1 via fluorescence in situ hybridization (FISH) studies or PCR-based testing. Patients with >1000/mm3 lymphoblasts in the peripheral blood that cannot undergo bone marrow biopsy and aspiration due to clinical condition are also eligible
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • Adequate organ function as confirmed by clinical/medical record
  • Patients must be at least 2 weeks from major surgery, radiation therapy, or participation in other investigational trials, and must have recovered from clinically significant toxicities related to these prior treatments
  • Patients must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee/Institutional Review Board prior to starting any screening or study-specific procedures
  • Females of childbearing potential will use effective contraception during treatment with InO and for at least 8 months after the last dose. Males with female partners of reproductive potential will use effective contraception during treatment with Inotuzumab Ozogamicin and for at least 5 months after the last dose. A patient is of childbearing potential if, in the opinion of the treating investigator, he/she is biologically capable of having children and is sexually active. Female patients who are not of childbearing potential (ie, meet at least one of the following criteria):; Have undergone hysterectomy or bilateral oophorectomy; or have medically confirmed ovarian failure; or are medically confirmed to be post-menopausal (cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause)
  • Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures

Who cannot take part

  • Any prior therapy for ALL except for limited treatment (≤ 7 days) with corticosteroids or hydroxyurea and a single dose of intrathecal therapy. Patients who are being treated with chronic steroids for other reasons (eg, asthma, autoimmune disorders) are eligible
  • Major surgery within ≤ 2 weeks before randomization
  • Medications known to predispose to Torsades de Pointes are prohibited throughout the treatment period of the study
  • Pregnant females; breastfeeding females; males with female partners of reproductive potential and females of childbearing potential not using highly effective contraception or not agreeing to continue highly effective contraception for a minimum of 5 months after the last dose of investigational product if male and 8 months after the last dose of investigational product if female
  • Isolated extramedullary disease
  • Current or chronic hepatitis B or C infection as evidenced by hepatitis B surface antigen and anti-hepatitis C antibody positivity, respectively, or known seropositivity for human immunodeficiency virus (HIV). HIV testing may need to be performed in accordance with local regulations or local practice. Patients with HIV but an undetectable viral load are eligible for enrollment
  • Unstable or severe uncontrolled medical condition (eg, unstable cardiac function or unstable pulmonary condition
  • Uncontrolled cardiac disease
  • History of chronic liver disease (eg, cirrhosis) or suspected alcohol abuse
  • History of hepatic veno-occlusive disease (VOD) or sinusoidal obstruction syndrome (SOS)
  • Evidence of uncontrolled current serious active infection including sepsis, bacteremia, fungemia, or patients with a recent history (within 4 months) of deep tissue infections such as fasciitis or osteomyelitis
  • Other severe acute, chronic medical, psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Study Lead Principal Investigator, would make the patient inappropriate for entry into this study
  • Concurrent active malignancy other than non-melanoma skin cancer, carcinoma in situ of the cervix, or localized prostate cancer that has been definitely treated with radiation or surgery. Patients with previous malignancies are eligible provided that they have been disease free for ≥2 years or are not currently requiring treatment
  • Burkitt's or mixed-lineage leukemia
  • Active central nervous system (CNS) leukemia
  • QTcF > 500 msec (based on the average of 3 consecutive ECGs)
  • Patients who are investigational site staff members or relatives of those site staff members or patients who are Pfizer employees directly involved in the conduct of the trial
  • Participation in other investigational studies during active treatment phase

Where in United States

  • University of Chicago Medical CenterChicago, United StatesContact: Wendy Stock, MDTaking people

About the trial

What the trial wants to find out

This research study will add an anti-cancer drug (called inotuzumab ozogamicin also known as "InO") to treatment for participants with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Doctors leading this study hope to learn if adding InO to standard induction treatment for Ph+ ALL will lead to quicker, complete molecular remission (where the disease is not detectable even with very sensitive testing techniques). The purpose of this research is to gather information regarding the effectiveness of InO in newly-diagnosed Ph+ ALL patients that have not yet received treatment.

The 5 groups in the trial

  • Induction/Consolidation Phase - All ParticipantsTreatment being tested

    All participants in this study will receive the same first round of treatment as part of induction/consolidation therapy. This treatment will use inotuzumab ozogamicin combined with anti-cancer drugs. The additional treatment that participants receive after this first round of treatment will vary based on the participant's response to induction therapy. This phase of treatment will last for 60 days. All participants in this arm will receive the following treatment: Treatment Course I (Induction Phase, 28 days): * Dasatinib 140mg daily continuous * Dexamethasone 10mg/m\^2 PO or IV Days 1-7 and Day 15-Day 22 * InO 0.8mg/m2 Day 8; 0.5mg/m2 D15, 0.5mg/m2 Day 22 * Intrathecal methotrexate 15mg Day 1, Day 28 Treatment Course II (Consolidation Phase, 28 days): * Dasatinib 140mg daily continuous * InO: If in CR/CRi 0.5mg/m2 Day 1, Day 8, Day 15; If not in CR/CRi 0.8mg/m2 on Day 1, 0.5mg/m2 Day 8 and Day 15 * Intrathecal methotrexate 15mg Day 1, Day 28

    Treatment: Inotuzumab ozogamicin, Dasatinib, Dexamethasone, and Methotrexate

  • Maintenance Phase - Participants in CMR (Schema 2 Regimen - Enrollment Completed)Treatment being tested

    Participants who no longer show any detectable signs of BCR-ABL1 (a cancer-causing gene) in response to the previous phase of induction/consolidation treatment (also known as being in "complete molecular remission" or CMR). Participants in this arm will receive treatment using dasatinib combined with POMP chemotherapy and intrathecal methotrexate. POMP chemotherapy consists of the drugs 6-Mercaptopurine + Vincristine + Methotrexate + Prednisone.

    Treatment: Dasatinib, Methotrexate, Vincristine, Ponatinib, Purinethol (6-Mercaptopurine), and Prednisone

  • Maintenance Phase - Participants Not in CMR (Schema 2 Regimen - Enrollment Completed)Treatment being tested

    Participants whose cancer responded to induction/consolidation treatment, but still shows detectable signs of BCR-ABL1 (a cancer-causing gene), so they are not in complete molecular remission (CMR). Participants in this arm will receive treatment using ponatinib combined combined with POMP chemotherapy and intrathecal methotrexate. A single 28-day cycle of inotuzumab will be given after initial 84 days of maintenance treatment if CMR has not been achieved. POMP chemotherapy consists of the drugs 6-Mercaptopurine + Vincristine + Methotrexate + Prednisone.

    Treatment: Inotuzumab ozogamicin, Methotrexate, Vincristine, Ponatinib, Purinethol (6-Mercaptopurine), and Prednisone

  • Interim/Maintenance Phase - Participants in CMR (Schema 3 Regimen )Treatment being tested

    Participants who no longer show any detectable signs of BCR-ABL1 (a cancer-causing gene) in response to the previous phase of induction/consolidation treatment (also known as being in "complete molecular remission" or CMR). Participants in this arm will receive treatment using dasatinib and intrathecal methotrexate.

    Treatment: Dasatinib and Methotrexate

  • Maintenance Phase - Participants Not in CMR (Schema 3 Regimen)Treatment being tested

    Participants whose cancer responded to induction/consolidation treatment, but still shows detectable signs of BCR-ABL1 (a cancer-causing gene), so they are not in complete molecular remission. Participants in this arm will receive treatment using ponatinib combined with intrathecal methotrexate. A single 28-day cycle of inotuzumab will be given after initial 84 days of maintenance treatment if CMR has not been achieved.

    Treatment: Methotrexate and Ponatinib

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase II Study of a Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia (ALL) Incorporating Inotuzumab Ozogamicin (InO)
Plain-language title
Tests adding inotuzumab ozogamicin to treatment for new Ph+ acute lymphoblastic leukemiaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Publications
Record updated
5 June 2026